Clay Siegall Contribution in the Field of Cancer Research Cannot be Overlooked

Among the many companies that have delved into cancer research over the last one to two decades, Seattle Genetics stands out as the leading company when it comes to innovation and expertise. At the center of the company’s excellence is Dr. Clay Siegall, its CEO of the last 15 years. Under the leadership of Siegall, who is also the firm’s president and board chairman, Seattle Genetics has witnessed massive advancements in cancer research, including developing several cancer therapies for those battling the life-threatening disease. Among the notable of these therapies include ADCETRIS®, an FDA-approved antibody drug conjugate. Consequently, its products are dominating markets in over 60 countries, with the stock tripling over a period of not more than five years.

Siegall’s Experience

Dr. Clay Siegall is a very accomplished man, with his experience in Genetics spanning over two decades. His first accomplishment was successful completion of a Ph.D. in Genetics from the internationally celebrated George Washington University. Equipped with his Ph.D., Siegall kicked off what would later turn out to be an excellent career at the Bristol-Myers Squibb Pharmaceutical Research Institute as a senior research investigator. Following a thorough service in the position, he earned a promotion to the rank of principal scientist. At this point, Siegall had already made a name for himself, and it was just a matter of few years before National Cancer Institute hired him to serve as a biotechnology fellow. Having accumulated all this experience, he set off on his own to establish Seattle Genetics.

More about Siegall

Siegall’s brilliance extends beyond cancer research. He has in the past shown great mobilization skills by single-handedly fundraising funds for his company to the tune of $1.2 billion. He is also a prolific scientific publisher, with about 70 articles and 15 patents to his name. In a nutshell, Siegall is not just helping patients; he is also aiding future research by these publications.

On March 28, 2016, Bizjournal reported that Clay Siegall and Seattle Genetics were on the verge of hiring an extra 350 employees. Siegall had revealed to the journal that 120 employees would be hired within that year, with 100 of them working in the U.S. and the rest in Switzerland.

Reference

http://www.bizjournals.com/seattle/blog/health-care-inc/2016/03/seattle-genetics-ambitious-plan-for-12-more-drugs.html